Study Summary:

This study is for people with a type of kidney cancer called clear cell renal cell carcinoma (ccRCC) that hasn't spread to other parts of the body. The study tests two drugs, lenvatinib and pembrolizumab, given before surgery to see if they can shrink the cancer. Lenvatinib works by stopping cancer cells from growing, and pembrolizumab helps the immune system attack the cancer.

Key Points:

• The study lasts about 12 weeks, with treatments every 3 weeks.
• Participants will visit the clinic for treatment and follow-ups.
• Risks include side effects from drugs or surgery complications.

Participants must have a certain stage of kidney cancer and meet specific health requirements. They cannot have other active cancers or certain health issues. This study aims to see if these drugs are safe and effective when given before surgery. After treatment, patients are monitored to ensure their safety and to evaluate how well the treatment worked.

Inclusion criteria include having a kidney mass and specific lab test results. Exclusion criteria include having metastatic disease or certain medical conditions. Participants must be able to comply with the study requirements and provide informed consent.